The antiviral effects of human microRNA miR‐302c‐3p against hepatitis B virus infection

Conventional treatments of chronic hepatitis B virus (HBV) infection rarely achieve a decline of serum hepatitis B surface antigen (HBsAg) levels and eradication of the virus.

[1]  T. Ochiya,et al.  Screening of microRNAs for a repressor of hepatitis B virus replication , 2018, Oncotarget.

[2]  Qiuran Xu,et al.  The tumor suppressive miR-302c-3p inhibits migration and invasion of hepatocellular carcinoma cells by targeting TRAF4 , 2018, Journal of Cancer.

[3]  T. Volz,et al.  Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. , 2017, Gastroenterology.

[4]  Ellen Van Damme,et al.  Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus , 2017, Antimicrobial Agents and Chemotherapy.

[5]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[6]  D. Gu,et al.  microRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2) , 2017, Oncotarget.

[7]  Kyun-Hwan Kim,et al.  Roles of hepatocyte nuclear factors in hepatitis B virus infection. , 2016, World journal of gastroenterology.

[8]  M. Bazinet,et al.  Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection , 2016, PloS one.

[9]  K. Chayama,et al.  Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. , 2016, Journal of hepatology.

[10]  Z. Gao,et al.  The miR-302/367 cluster: a comprehensive update on its evolution and functions , 2015, Open Biology.

[11]  T. Evans,et al.  Orchestrating liver development , 2015, Development.

[12]  Y. Mizuguchi,et al.  Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication. , 2015, World journal of hepatology.

[13]  T. Joh,et al.  Validation of Cross-Genotype Neutralization by Hepatitis B Virus-Specific Monoclonal Antibodies by In Vitro and In Vivo Infection , 2015, PloS one.

[14]  B. Autran,et al.  Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.

[15]  C. Rice,et al.  The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. , 2015, Immunity.

[16]  T. Ochiya,et al.  microRNAs and Hepatitis B. , 2015, Advances in experimental medicine and biology.

[17]  Zhao-You Tang,et al.  MiR-302c inhibits tumor growth of hepatocellular carcinoma by suppressing the endothelial-mesenchymal transition of endothelial cells , 2014, Scientific Reports.

[18]  Hussein H. Aly,et al.  Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. , 2014, Biochemical and biophysical research communications.

[19]  Alan McLachlan,et al.  Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Ding-Shinn Chen,et al.  High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. , 2012, Gastroenterology.

[21]  Paul J Rider,et al.  A liver‐specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Y. Shaul,et al.  Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[23]  Caitlin R. Ondracek,et al.  Multiple nuclear receptors may regulate hepatitis B virus biosynthesis during development. , 2011, The international journal of biochemistry & cell biology.

[24]  B. McMahon,et al.  Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus , 2010, Hepatology.

[25]  V. Wong,et al.  Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[27]  F. Zoulim.  New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. , 2005, Journal of hepatology.

[28]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[29]  J. Ou,et al.  Regulation of Hepatitis B Virus Core Promoter by Transcription Factors HNF1 and HNF4 and the Viral X Protein , 2004, Journal of Virology.

[30]  M. Yaniv,et al.  Nuclear Covalently Closed Circular Viral Genomic DNA in the Liver of Hepatocyte Nuclear Factor 1α-Null Hepatitis B Virus Transgenic Mice , 2001, Journal of Virology.

[31]  F. Chisari,et al.  High-level hepatitis B virus replication in transgenic mice , 1995, Journal of virology.